Literature DB >> 35149516

Covid-19: What do we know about omicron sublineages?

Elisabeth Mahase1.   

Abstract

Entities:  

Year:  2022        PMID： 35149516     DOI： 10.1136/bmj.o358

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.

Authors:  Prerna Arora; Lu Zhang; Nadine Krüger; Cheila Rocha; Anzhalika Sidarovich; Sebastian Schulz; Amy Kempf; Luise Graichen; Anna-Sophie Moldenhauer; Anne Cossmann; Alexandra Dopfer-Jablonka; Georg M N Behrens; Hans-Martin Jäck; Stefan Pöhlmann; Markus Hoffmann
Journal:  Cell Host Microbe       Date:  2022-05-06       Impact factor: 31.316

2.  Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions.

Authors:  Saathvik R Kannan; Austin N Spratt; Kalicharan Sharma; Ramesh Goyal; Anders Sönnerborg; Subbu Apparsundaram; Christian L Lorson; Siddappa N Byrareddy; Kamal Singh
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

Review 3.  Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions.

Authors:  Bin Wang; Lei Zhang; Yongqiang Wang; Tong Dai; Ziran Qin; Fangfang Zhou; Long Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-04-29

4.  The severity of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant, in Marseille, France, December 2021-February 2022.

Authors:  Philippe Gautret; Van T Hoang; Marie T Jimeno; Jean-Christophe Lagier; Pascal Rossi; Pierre E Fournier; Philippe Colson; Didier Raoult
Journal:  J Med Virol       Date:  2022-04-09       Impact factor: 20.693

Review 5.  Is Omicron the end of pandemic or start of a new innings?

Authors:  Swarnali Das; Sovan Samanta; Jhimli Banerjee; Amitava Pal; Biplab Giri; Suvrendu Sankar Kar; Sandeep Kumar Dash
Journal:  Travel Med Infect Dis       Date:  2022-04-23       Impact factor: 20.441

6.  Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.

Authors:  Lorenza Bellusci; Gabrielle Grubbs; Fatema Tuz Zahra; David Forgacs; Hana Golding; Ted M Ross; Surender Khurana
Journal:  Nat Commun       Date:  2022-08-08       Impact factor: 17.694

7.  Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes.

Authors:  Rhiane Moody; Sabrina Sonda; Fay H Johnston; Kylie J Smith; Nicola Stephens; Michelle McPherson; Katie L Flanagan; Magdalena Plebanski
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

8.  Two Years of COVID-19 Pandemic: How the Brazilian Serie A Championship Was Affected by Home Advantage, Performance and Disciplinary Aspects.

Authors:  Aldo Coelho Silva; Adriana Souza Amaral; Lucas Alves Facundo; Melissa Talita Wiprich; Leandro Rechenchosky; Wilson Rinaldi
Journal:  Int J Environ Res Public Health       Date:  2022-08-19       Impact factor: 4.614

Review 9.  Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.

Authors:  Hao Zhou; Michelle Møhlenberg; Jigarji C Thakor; Hardeep Singh Tuli; Pengfei Wang; Yehuda G Assaraf; Kuldeep Dhama; Shibo Jiang
Journal:  Clin Microbiol Rev       Date:  2022-06-06       Impact factor: 50.129

Review 10.  Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?

Authors:  Manish Dhawan; AbdulRahman A Saied; Saikat Mitra; Fahad A Alhumaydhi; Talha Bin Emran; Polrat Wilairatana
Journal:  Biomed Pharmacother       Date:  2022-08-15       Impact factor: 7.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.